期刊文献+

^(18)F-FDG符合线路正电子显像对肺癌的诊断价值研究 被引量:3

Diagnostic Value of ^(18)F-FDG Coincidence PET on Lung Cancer
下载PDF
导出
摘要 目的探讨18F-FDG符合线路正电子显像对肺癌的诊断价值。方法利用双探头符合线路SPECT对105例可疑肺癌患者进行18F-FDG正电子显像,并进行同机CT图像融合。利用感兴趣技术计算病变与对侧正常部位的放射性计数比值(T/NT)对病灶进行半定量分析,比较视觉分析和半定量分析18F-FDG符合线路正电子显像对肺癌的诊断效能。结果视觉分析对肺癌的诊断灵敏度为92.13%,特异性为56.25%,准确性为86.66%。以T/NT≥2.7为判断阈值,半定量分析的灵敏度为95.5%,特异性为81.3%,准确性为93.3%。结论18F-FDG符合线路正电子显像视觉分析结合半定量分析对肺癌的诊断具有较高的灵敏度、特异性和准确性,可应用于肺癌的诊断和鉴别诊断。 Objective To investigate the diagnostic value of ^18F-FDG coincidence PET on lung cancer. Methods ^18F-FDG PET imaging was performed on 105 patients suspecte.d lung cancer with dual-head coincidence SPECT device. Visual analysis and semi-quantitative method with ROI were performed on lung lesions of ^18 F-FDG uptake. Target to no-target active ratio (T/NT) of lung lesions were calculated. Results With visual analysis, the diagnostic sensitivity, specificity and accuracy of ^18 F-FDG coincidence imaging were 92.13%, 56.25%, 86.66%, respectively. With semi-quantitative analysis, the diagnostic sensitivity, specificity and accuracy of ,^18-FDG coincidence imaging were 95.5%, 81.3% and 93.3%, respectively according to T/NT≥2.7 threshold. Conclusion ^18F-FDG coincidence PET imaging based on visual analysis and semi-quantitative analysis has high diagnostic sensitivity, specificity and accuracy for lung cancer, ^18 F-FDG coincidence PET imaging is useful in diagnosis and differential diagnosis of lung cancer.
出处 《河北医药》 CAS 2008年第12期1864-1865,共2页 Hebei Medical Journal
基金 河北省科技支撑计划项目(编号:0727611017)
关键词 肺肿瘤 诊断 鉴别 体层摄影术 发射型计算机 单光子 脱氧葡萄糖 lung neoplasm diagnosis, differential tomography, emission, computed, single-photon deoxyglucose
  • 相关文献

参考文献8

  • 1Ak I, Blokland JAK, Pauwels EKJ, et al. The clinical value of 18 F-FDG detection with a dual-head coincidence camera: a review. Eur J Nucl Med, 2001,28: 763-772.
  • 2Bunyaviroch T, Coleman E. PET evaluation of lung cancer. J Nucl Med, 2006,47:451-469.
  • 3郑建国,屈婉莹,姚稚明,王梅,罗志福,管一晖,王全师,陈秋松,张永学,黄庆娟,尹吉林,李亚明,刘庆伟,郭万华.^18F-FD GPET/CT对不同大小孤立性肺结节的诊断价值[J].中华核医学杂志,2008,28(3):170-173. 被引量:23
  • 4边艳珠,魏强,吴大勇,张文艳,李金福,刘永宁.^(18)F-FDG符合线路显像在非小细胞肺癌治疗前分期中的价值[J].中国医学影像技术,2006,22(11):1749-1751. 被引量:3
  • 5王荣福 秦乃珊.双探头符合线路断层显像和增强CT扫描诊断肺孤立性病变的比较研究[J].亚洲核医学杂志,2001,1(1):5-8.
  • 6Oturai PS, Mortensen J, Enevoldsen H, et al.γ-camera ^18 F-FDG PET in diagnosis and staging of patients presenting with suspected lung cancer and comparison with dedicated PET. J Nucl Med,2004,45:1351-1357.
  • 7梁颖慈,唐安戊,徐浩.^(18)F-FDG PET延迟显像鉴别诊断原发性肺癌[J].中华核医学杂志,2004,24(1):27-29. 被引量:37
  • 8Pauleit D, Stoffels G, Schaden W, et al. PET with O-( 2-^18 F-Fluoroethyl)-L- tyrosine in peripheral tumors: first clinical results. J Nucl Med, 2005,46: 411-416.

二级参考文献16

共引文献67

同被引文献36

  • 1Rajeswaran A,Trojan A,Burnand B,et al.Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma:a systematic review of randomized controlled trials[J].Lung Cancer,2008,59(1):1-11.
  • 2Govindan R,Morgensztern D,Kommor MD,et al.Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6(4):790-795.
  • 3Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346:92-98.
  • 4Trillet-Lenoir V,Freyer G,Kaemmerlen P,et al.Assessment of tumour response to chemotherapy for metastatic colorectal cancer:accuracy of the RECIST criteria[J].Br J Radiol,2002,75(899):903-908.
  • 5Chou WC,Huang SF,Yeh KY,et al.Different responses to gefitinib in lung adenocarcinoma coexpressing mutant and wild-type epidermal growth factor receptor genes[J].Jpn J Clin Oncol,2006,36:523-526.
  • 6Suzuki C,Jacobsson H,Hatschek T,et al.Radiologic measurements of tumor response to treatment:practical approaches and limitations[J].Radiographics,2008,28(2):329-44.
  • 7Nisman B,Biran H,Heching N,et al.Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer:association of marker changes after two chemotherapy cycles with different measures of clinical response and survival[J].Br J Cancer,2008,98(1):77-79.
  • 8Armstrong AJ,Garrett-Mayer E,De Wit R,et al.Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer[J].Clin Cancer Res,2010,16(1):203-211.
  • 9Hammad N,Heilbrun LK,Philip PA,et al.CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy[J].Asia Pac J Clin Oncol,2010,6(2):98-105.
  • 10Zaeska M,Szturmowicz M,Zych J,et al.The significance of the serum tumour markers as a prognostic and predictor factors in nonsmall cell lung cancer patients[J].Pneumonol Alergol Pol,2005,73(3):270-276.

引证文献3

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部